Joseph Papa

Shares of Valeant Pharmaceuticals Intl Inc (NYSE: VRX) gained more than 3.5 percent early Thursday morning after the company announced the sale of one of its business units. Valeant has agreed to sell its iNova Pharmaceuticals business for $930 million to a group advised and managed by major...

Perrigo Company plc Ordinary Shares (NYSE: PRGO) is considering the potential sale of its non-core businesses, including the lucrative royalty stream from MS drug Tysabri and the prescription pharmaceutical segment. Argus’ Jacob Kilstein maintains a Hold rating on the company. Concerns...

Shares of Valeant Pharmaceuticals Intl Inc (NYSE: VRX) soared Tuesday after The Wall Street Journal reported the company is in talks to sell its Salix unit for up to $10 billion. Salix, a leader in the gastrointestinal market, was acquired by Valeant back in February 2015 for $158 per share,...

Following the departure of CEO Joseph Papa, along with the subsequent 17 percent cut in the 2016 earnings guidance and the associated uncertainty regarding its strategy, Perrigo Company plc Ordinary Shares (NYSE: PRGO) have taken a hit. Argus’ Jacob Kilstein maintains a Hold rating on the...

Democratic presidential nominee Hillary Clinton is probably one of the main people responsible for Valeant Pharmaceuticals Intl Inc (NYSE: VRX)’s recent ailment – it was largely her words that spurred the 74 percent decline in the company’s sales year-to-date. In addition, a few...

Valeant Pharmaceuticals Intl Inc (NYSE: VRX)'s stock got a boost on Wednesday after the U.S. Food and Drug Administration (FDA) approved the company's RELISTOR Tablets for the treatment of opioid-induced constipation in adults with chronic non-cancer pain. Valeant said in a press release that it...

Shares of Valeant Pharmaceuticals Intl Inc (NYSE: VRX) have plunged roughly 90 percent over the past year and the company's mounting debt load is having investors think the company's only path towards long-term survival is selling off core assets. Billionaire hedge fund manager and...

Valeant Pharmaceuticals Intl Inc (NYSE: VRX) CEO Joseph Papa bought 202,000 shares at $24.48 per share Monday morning. The purchase came after key events last week. Tuesday: Reported Q1 Adj. EPS $1.27 vs $1.37 Est., Sales $2.4B vs $2.38B Est. Tuesday: Cut FY16 Sales Outlook from $11B-$11....

The Wall Street Journal reported late Thursday afternoon that prior to hiring Joseph Papa as CEO, Valeant Pharmaceuticals Intl Inc (NYSE: VRX) received an acquisition proposal from Japan's Takeda Pharmaceutical and private equity firm TPG. The Wall Street Journal, citing "people familiar with the...

Andrew Left and his research firm, Citron Research, previously trashed Valeant Pharmaceuticals Intl Inc (NYSE: VRX) business, calling it a "Pharmaceutical Enron." Following his harsh comments, it may be surprising to some investors to find out that Left is now long Valeant. Speaking...

The Wall Street Journal reported Wednesday evening that Valeant Pharmaceuticals Intl Inc (NYSE: VRX) is set to implement "sweeping changes" to its board of directors. The Wall Street Journal, citing "people familiar with the matter," stated that five of Valeant's long-standing directors have...

On April 25, Valeant Pharmaceuticals Intl Inc (NYSE: VRX) announced that the former CEO of Perrigo Company plc Ordinary Shares (NYSE: PRGO), Joseph Papa, would replace the outgoing Mike Pearson as chairman and CEO. Rodman & Renshaw’s Raghuram Selvaraju reiterated a Buy rating on Valeant...

The next chapter in the Valeant Pharmaceuticals Intl Inc (NYSE: VRX) story began today when the company named Joseph Papa as its new CEO. Shareholders are hoping that Papa can right the ship after a whirlwind of controversy has driven Valeant’s share price down 63.1 percent so far in 2016...

Shares of Perrigo Company plc Ordinary Shares(NYSE: PRGO) fell more than 5 percent after a Wall Street Journal report said its Chief Executive Joseph Papa may move to Valeant Pharmaceuticals Intl Inc (NYSE: VRX), whose shares surged more than 8 percent on the speculation. CNBC's Jim Cramer said if...